3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Vascular Diseases
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Interventions
Dexamethasone
110
Cyclophosphamide
99
Melphalan
91
Bortezomib
68
Peripheral Blood Stem Cell Transplantation
63
Lenalidomide
57
fludarabine phosphate
55
Busulfan
53
Filgrastim
50
Antilymphocyte Serum
38
Tacrolimus
37
Thalidomide
36
Radiotherapy
36
Mycophenolic Acid
32
fludarabine
28
Cyclosporine
26
Methotrexate
25
Etoposide
22
Calcium Dobesilate
22
Prednisone
21
Whole-Body Irradiation
20
Methylprednisolone
20
sargramostim
19
pomalidomide
19
Granulocyte Colony-Stimulating Factor
18
carfilzomib
16
daratumumab
15
Cord Blood Stem Cell Transplantation
14
Carmustine
14
Rituximab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Plasma Cell
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled